|
Taken from WWW.pubmed.gov (testosterone studies)
Climacteric. 2007 Oct;10(5):386-92.
Could androgens protect middle-aged women from cardiovascular events? A population-based
study of Swedish women: The Women's Health in the Lund Area (WHILA) Study.
Khatibi A, Agardh CD, Shakir YA, Nerbrand C, Nyberg P, Lidfeldt J, Samsioe G.
Department of Clinical Sciences in Lund, Lund University, and Department of Gynecology and Obstetrics,
Lund University Hospital, Sweden.
OBJECTIVE: The aim of this analysis was to delineate perceived associations between androgens and
cardiovascular events in perimenopausal women.
DESIGN: A cross-sectional, population-based study of 6440 perimenopausal women aged 50-59 years,
living in Southern Sweden. In all, 461 (7.1%) women were premenopausal (PM), 3328 (51.7%) postmenopausal
without hormone therapy (HT) (PM0) and 2651 (41.2%) postmenopausal with HT (PMT). For further
comparisons, 104 women (1.6%) who reported cardiovascular disease (CVD) were studied in detail; 49 had
had a myocardial infarction, 49 a stroke and six women both events. For each woman with CVD, two matched
controls were selected (n=208).
RESULTS: In the matched controlled series, androstenedione levels were lower (p<0.005) in cases. Cases
with hormone therapy had also lower testosterone levels than matched controls (p=0.05). In the total
cohort, by using multiple logistic regression analyses, testosterone was positively associated with low
density lipoprotein cholesterol (p<0.001) and high density lipoprotein cholesterol (HDL-C) (p<0.001) in
all women, but negatively associated with levels of triglycerides in both the PM0 (p<0.001) and PMT
(p<0.001) groups. Androstenedione levels were positively associated with HDL-C (p<0.05) and negatively
with triglycerides (p<0.05) in the PM group.
CONCLUSION: Women with cardiovascular disease had lower serum androgen levels, particularly women using
hormone replacement therapy, even when controlled for lipids and other potential risk factors.
PMID: 17852141 [PubMed - in process]
|
